The $2 Million Cure Problem

A scientific breakthrough becomes medical progress only when the systems around it allow people to reach it, complete it, and live with its consequences.

Months ago, my friend Lydie Marc asked me to look into gene therapy for sickle cell disease. She wanted to understand Medicaid's role, whether patients could realistically reach treatment, and what the systems being built around these therapies might mean for the industry.

I thought I was chasing a drug-pricing question. I was really chasing a harder one: What counts as medical progress?

On July 1, 2026, the FDA expanded CASGEVY, the first approved medicine to use CRISPR gene editing, to children as young as 2 with sickle cell disease and recurrent vaso-occlusive crises. A child can now become eligible for a therapy designed to change the biology of the disease before decades of pain and organ damage accumulate. That is extraordinary. It is also the beginning of the story, not the end.

The challenge is no longer only whether we can make a cell therapy that works. It is whether we have the systems in place to turn a multimillion-dollar, transplantation-level intervention into durable and equitable access.

What These Therapies Actually Do

Sickle cell disease begins with a genetic change in beta-globin, a component of hemoglobin. Under low-oxygen conditions, hemoglobin S can bind together. Red blood cells become rigid, break down early, and obstruct small vessels. The result is not just an occasional pain crisis. It is a lifelong disease that can damage nearly every organ.

CASGEVY does not correct the sickle mutation itself. Clinicians collect a patient's own blood-forming stem cells, and CRISPR edits a regulatory region of BCL11A. That gene helps switch fetal hemoglobin off after birth. The edit turns fetal hemoglobin production back on in red cells. Because fetal hemoglobin does not sickle in the same way, it helps keep cells flexible and reduces vaso-occlusion.

LYFGENIA takes a different route. A lentiviral vector adds a modified beta-globin gene to the patient's stem cells, allowing them to produce an anti-sickling hemoglobin. CASGEVY is gene editing. LYFGENIA is gene addition. Both use a patient's own cells, so neither requires a matched donor.

The clinical results are powerful. In the pivotal published CASGEVY analysis, 29 of 30 evaluable patients went at least 12 consecutive months without a severe vaso-occlusive crisis, and all 30 avoided hospitalization for a severe crisis for at least 12 consecutive months. LYFGENIA's label reports that 30 of 32 evaluable patients were free from severe vaso-occlusive events and 28 of 32 were free from all vaso-occlusive events during the primary assessment period.

Those numbers justify real hope. They do not settle the lifetime question. Follow-up is measured in years, while many patients now eligible are children. CASGEVY requires long-term follow-up totaling 15 years. LYFGENIA carries an FDA boxed warning for hematologic malignancy and requires lifelong monitoring. Potentially curative and functionally transformative are more honest than declaring victory.

One Time Is Not One Day

The phrase one-time therapy makes the treatment sound like a single infusion. Technically, the dose is given once. Practically, the infusion sits in the middle of a demanding care journey.

For CASGEVY, patients may receive weeks of red-cell transfusions before collection. They stop or change certain medications. Stem cells are mobilized into the bloodstream and collected by apheresis, sometimes across multiple cycles. A separate backup collection is stored in case the edited cells do not engraft. The individualized product is manufactured and tested. Only then does the patient receive myeloablative conditioning, usually four days of high-dose busulfan, to clear space in the bone marrow. The cells are infused, and the patient remains in the hospital until the new marrow begins to recover.

The conditioning is not a side detail. It suppresses blood counts, creates infection and bleeding risk, and can cause infertility. It is one reason the CMS access model requires participating manufacturers to finance defined fertility-preservation services.

It may be a one-time gene therapy. It is not a one-day treatment.

Coverage Is Not Access

Insurance coverage is one gate. It is not the whole path. A patient must be identified and referred, meet clinical and payer criteria, decide that the expected benefit is worth the risks, reach a qualified center, complete cell collection, wait for manufacturing, tolerate conditioning, receive the infusion, recover, and return for years of monitoring.

The current CASGEVY label offers a useful warning about this funnel. In the adult and adolescent trial, 63 people enrolled, 58 started mobilization, and 44 received the infusion. Six could not receive CASGEVY because an adequate cell collection could not be obtained. A clinical trial is not the real world, so those figures are not a population access rate. They do show that even after enrollment, the route to infusion has meaningful attrition.

Choice matters too. A study of adults with sickle cell disease and parents of children with the disease found that people were generally willing to consider gene therapy, but risk tolerance changed with symptom severity and expected benefit. Access should include the ability to say yes or no through informed, preference-sensitive decision-making. A system has not succeeded simply because it can issue an authorization.

Cost Effective Is Not Affordable

CMS cites a $2.2 million list price for CASGEVY and $3.1 million for LYFGENIA. Those figures are attention-grabbing, but price, value, and budget impact answer different questions.

Before either therapy was approved, the Institute for Clinical and Economic Review estimated that both could meet common cost-effectiveness thresholds at prices between $1.35 million and $2.05 million. The estimate modeled lifetime health gains and carried major uncertainty about durability. It was a value benchmark, not a statement that any payer could comfortably write the check.

A commercial-insurance study estimated sickle-cell-attributable medical costs of roughly $1.6 million for women and $1.7 million for men from birth through age 64. That does not prove a $2.2 million list price is fair. The study excluded Medicaid beneficiaries, indirect costs, older ages, and many burdens that matter to patients and families. It answers a different question.

The budget problem is about timing and volume. One pre-approval model assumed a $1.85 million therapy, 7% annual uptake among eligible patients, and a cure. Under those assumptions, the average one-year impact across ten high-prevalence state Medicaid programs was nearly $30 million. The exact estimate is dated and hypothetical. The structural point remains: lifetime value can be large while this year's budget cannot absorb everyone who might benefit.

Victor Roy traces the same tension in the hepatitis C era in Capitalizing a Cure. A cure could be clinically valuable and cost-effective while its launch price still triggered restrictions because public programs could not treat the whole eligible population at once. Cost-effective and affordable were never synonyms.

Value for Whom

For a patient, value may mean fewer crises, fewer hospitalizations, less fear, and a chance to pursue work, school, family, or ordinary plans without disease dictating every decision. The patient also bears conditioning toxicity, infertility risk, time away from home, and uncertainty that extends beyond the current evidence.

For a family, value may be relief from crisis caregiving. The burden may be months of logistics, travel, missed work, and supporting recovery. For a state Medicaid program, value may be fewer future admissions and less chronic care. The burden is a large payment today, possibly for benefits that another payer will capture years later. For a hospital, offering the therapy can transform care, but it requires beds, specialized staff, cell-collection capacity, coordination, and confidence that reimbursement will arrive.

The Medicaid Experiment

CMS estimates that 50% to 60% of people living with sickle cell disease have Medicaid. Its Cell and Gene Therapy Access Model now includes 32 states, the District of Columbia, and Puerto Rico, representing an estimated 84% of Medicaid beneficiaries with sickle cell disease.

Instead of asking every state to negotiate and administer a separate agreement, CMS negotiated common terms with manufacturers. Participating states use outcomes-based arrangements. If treatment falls short of agreed outcomes, the manufacturer returns part of the payment. CMS handles shared outcome definitions, data reconciliation, and evaluation.

The model reaches beyond the drug invoice. Manufacturers finance collection, freezing, and storage of reproductive material for at least five and up to 15 years. States must ensure access to at least one qualified treatment center, including an out-of-state center when necessary. A national registry will collect clinical data and voluntary patient-reported outcomes such as pain, fatigue, function, mental health, and financial burden for up to five years.

That is an important design choice. It recognizes that value cannot be inferred from hemoglobin alone. It has to become visible in a person's life.

That is why this is more than a sickle cell payment policy. If it works, CMS will have built part of the infrastructure for a future with more expensive, one-time interventions. If it fails, we will learn that negotiating the product price was not enough.

The Equity Test

The breakthrough arrived after a long history of neglect. A JAMA Network Open study examining the 2008 through 2018 research environment found mean annual federal funding of $812 per person with sickle cell disease versus $2,807 per person with cystic fibrosis. Foundation spending showed a much larger disparity. These are historical numbers, not a description of 2026 funding. They document the terrain from which this scientific achievement emerged.

Uché Blackstock's Legacy adds the part a funding table cannot capture: a two-tier health system, under-resourced care settings, and the stigma people with sickle cell disease have faced when seeking treatment for pain. Technology does not automatically undo those structures. A therapy can be available on paper and still be out of reach for someone who lacks a trusted hematologist, transportation, paid leave, a caregiver, or confidence that the system will treat their pain and priorities with respect.

Equity is not the existence of a gene therapy. It is whether referral, authorization, fertility preservation, treatment completion, and durable outcomes improve for the people who have borne both the disease and the history around it.

The Industry Lesson

For manufacturers, the CMS model offers a clearer path into multiple state programs, common measurement, less duplicated negotiation, and potentially more predictable revenue. CMS described those benefits in its original rationale. In exchange, manufacturers accept discounts, outcomes-linked rebates, fertility-support obligations, and real-world measurement.

The commercial pathway is beginning to form. Vertex reported 64 CASGEVY infusions globally across sickle cell disease and beta thalassemia in 2025, with $116 million in revenue. In the second quarter of 2026, revenue reached $76 million. These company-reported figures show momentum, but they do not tell us how many U.S. patients with sickle cell disease were treated or whether the business is profitable.

The more durable industry benefit may be institutional. Common contracts, defined outcomes, a national registry, provider payment rules, treatment-center relationships, and patient-support expectations can reduce friction for the therapies that follow. Yet the model creates lasting value for industry only if it also creates lasting value for patients and public payers. Otherwise, it becomes a reimbursement mechanism without legitimacy.

What Would Count as Success

The first test is how many eligible people are referred, make an informed decision, complete collection, reach infusion, and remain connected to follow-up. The second is whether severe crises, hospitalizations, pain, fatigue, organ damage, and financial burden improve for years. The third is whether geography, income, race, and insurance stop predicting who can complete the journey. The fourth is whether states can sustain access without crowding out other care. The fifth is whether manufacturers remain rewarded when promised outcomes persist and repay part of the cost when they do not.

CMS says evaluation reports will begin in 2027. Until those results arrive, the right posture is neither cynicism nor celebration. It is disciplined hope.

Medicine has crossed an extraordinary threshold in sickle cell disease. The next test is whether the systems around a multimillion-dollar, potentially curative therapy can deliver its value equitably, safely, and sustainably. A breakthrough that patients cannot reach is a scientific victory without corresponding medical progress. The work now is to prevent that split.

With thanks to Lydie Marc for prompting the question and reviewing an earlier draft.